Physician profile
Rukhsar Karim Machiwalla
NPI 1932700259
$3,394.48
in general payments reported to CMS, 2019-2025
20 companies · $3,394 in 2025
The $3,394 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $3,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,389 · Education: $5.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,389.03 |
| Education | $5.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $422.54 | 2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $399.05 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $377.32 | 2025 | Caplyta |
| Lundbeck LLC | $322.45 | 2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $320.27 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $286.01 | 2025 | Fanapt |
| Abbvie INC. | $236.64 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $221.36 | 2025 | Austedo Xr, Uzedy |
| E.R. Squibb & Sons, L.L.C. | $153.03 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $134.47 | 2025 | Auvelity |
| Bausch Health US, LLC | $97.48 | 2025 | Aplenzin |
| Braeburn INC. | $83.62 | 2025 | Brixadi |
| Alkermes, INC. | $76.61 | 2025 | Aristada, Lybalvi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $72.01 | 2025 | Rejoyn |
| Corium, LLC | $57.62 | 2025 | Azstarys |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $46.20 | 2025 | Zurzuvae |
| Indivior INC. | $38.17 | 2025 | Sublocade |
| Almatica Pharma LLC | $17.08 | 2025 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $16.55 | 2025 | Jornay Pm |
| Tris Pharma INC | $16.00 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rukhsar Machiwalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.